Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: The ORDET cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 3, 2010, Pages 729-737

  Schernhammer, Eva S ^a,b,c   Berrino, Franco ^d   Krogh, Vittorio ^d   Secreto, Giorgio ^d   Micheli, Andrea ^d   Venturelli, Elisabetta ^d   Grioni, Sara ^d   Sempos, Christopher T ^e   Cavalleri, Adalberto ^d   Schünemann, Holger J ^e,f,h   Strano, Sabrina ^g   Muti, Paola ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY AT BUFFALO   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g Molecular Chemioprevention Unit   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 SULPHATOXYMELATONIN; CREATININE; MELATONIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; HUMAN; LIGHT DARK CYCLE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; URINE LEVEL;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; PREMENOPAUSE; RADIOIMMUNOASSAY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949697894     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1229     Document Type: Article

References (52)

1. Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 1998;3:13-22.
2. Czeisler CA, Klerman EB. Circadian and sleep-dependent regulation of hormone release in humans. Recent Prog Horm Res 1999;54:97-130.
3. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999;284:2177-81.
4. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985;60:1166-73.
5. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998;24:58-61.
6. Cook MR, Graham C, Kavet R, Stevens RG, Davis S, Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res 2000;28:41-7.
7. Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab 1981;53:645-50.
8. Leibenluft E, Feldman-Naim S, Turner EH, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. Biol Psychiatry 1996; 40:731-5.
9. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol 1987;27:445-52.
10. Wetterberg L. Melatonin in humans physiological and clinical studies. J Neural Transm Suppl 1978;13:289-310.
11. Schernhammer ES, Hankinson SE. Light at night: a novel risk factor for cancer in shift workers? Clin Occup Environ Med 2003;3:263-78.
12. Stevens RG, Blask DE, Brainard GC, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect 2007;115:1357-62.
13. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 1978;2:814-6.
14. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95.
15. Vijayalaxmi , Thomas CR, Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20: 2575-601.
16. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84.
17. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev 2009;18:74-9
18. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2008;100:898-905.
19. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 2004;96:475-82.
20. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 2005;97:1084-7.
21. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
22. Berrino F, Pisani P, Muti P. Prospective study of hormones and diet in the aetiology of breast cancer. In: Riboli E, Saracci R, editors. Diet, hormones, and cancer: methodological issues for prospective studies IARC Technical Report Number 4. Lyon: IARC; 1988, p. 34-38.
23. Parkin DM, Whelan S, Ferlay J. Cancer Incidence in five continents, vol. VII. IARC Scientific Publications Number 143. Lyon: IARC; 1997.
24. Waterhouse J, Muir C, Shanmugaratnam K. IARC Scientific Publications. Lyons: IARC; 1982.
25. Barba M, Cavalleri A, Schunemann HJ, et al. Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer. Int J Biol Markers 2006;21:242-5.
26. Bartels H, Bohmer M, Heierli C. [Serum creatinine determination without protein precipitation]. Clin Chim Acta 1972;37:193-7.
27. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-60.
28. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001;93:1563-8.
29. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557-62.
30. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 2001;12:74-7.
31. Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982;216:1003-5.
32. Schernhammer ES, Kroenke CH, Dowsett M, Folkerd E, Hankinson SE. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res 2006;40:116-24.
33. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005;113:192-200.
34. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991;67:1681-4.
35. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 1989;64:426-33.
36. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981;52:281-94.
37. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J Pineal Res 1997; 23:53-8.
38. Danforth DNJ, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 1985;3:941-8.
39. Falkson G, Falkson HC, Steyn ME, Rapoport BL, Meyer BJ. Plasma melatonin in patients with breast cancer. Oncology 1990;47:401-5.
40. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 1998;24:230-8.
41. Lissoni P, Bastone A, Sala R, et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur J Cancer Clin Oncol 1987;23:949-57.
42. Lissoni P, Crispino S, Barni S, et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology 1990;47:275-7.
43. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J. 6-Sulphatoxymelatonin production in breast cancer patients. J Pineal Res 1990;8:269-76.
44. Bartsch C, Bartsch H, Fluchter SH, Attanasio A, Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J Pineal Res 1985;2:121-32.
45. Schernhammer E, Berrino F, Krogh V, et al. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in postmenopausal women: the ORDET cohort. J Natl Cancer Inst 2008;100:898-905.
46. Schernhammer E, Kroenke C, Laden F, Hankinson S. Night Work and Melatonin Levels in Women Participating in the Nurses' Health Study II: Associate with Breast Cancer Risk. 2nd Symposium of the Dana-Farber/Harvard Cancer Center Program in Breast Cancer, Boston. 2005.
47. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009; 9 Suppl 2:S73-81.
48. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev 2009;18:74-9.
49. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005;97:125-34.
50. Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol 2003;56:679-82.
51. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004;80:1721S-4S.
52. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol 2004;16:19-25.